DECCO, Inc. Serves as Process Piping Contractor for Award Winning CRISPR Therapeutics Manufacturing Facility

Project Recognized with 2022 International Society of Pharmaceutical Engineering Facility of the Year Award for Innovation

The International Society of Pharmaceutical Engineering (ISPE) has announced that CRISPR Therapeutics’ new manufacturing facility in Framingham, Massachusetts was awarded a Facility of the Year Award (FOYA) for Innovation based on the innovative design of the facility, which provides an end-to-end solution for production and fills operations.

DECCO, Inc. served as process piping contractor for the 55,000-sf interior fit-out of existing shell space for the new cGMP biologics manufacturing facility, including lab spaces, MST labs, warehouse, utilities, and office space.  Learn more about this award-winning project

Notable innovations in this facility include:

  • Digital systems and automation at all levels of the operation allow continuous monitoring and efficient product production and release.
  • A flexible utilization model allows for concurrent production of multiple products at various stages of development.
  • Independent and/or redundant utilities supplying individual clean rooms allow for continuous production without the need for a facility-wide maintenance shutdown.
  • Facility Vaporized Hydrogen Peroxide (FVHP) system to support rapid product changeover and reduction in the use of environmentally harmful chemicals.

“DECCO was pleased to work with the team at CRISPR, DPS, TRIA Design and Commodore Builders to bring this project to fruition,” notes Kyle Reagan, CEO, DECCO, Inc. “We collaborated with this project team to understand the mission of this unique project, overcome challenges, and provide quality craft professionals to support process piping services. Congratulations on a stellar project.”

FOYA is the premier global awards program recognizing innovation and creativity in manufacturing facilities serving the regulated healthcare industry. The award-winning projects selected by the FOYA program set the standard for pharmaceutical facilities of the future by demonstrating excellence in facility design, construction, and operations.